Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation.

Journal: Current problems in cardiology

Volume: 42

Issue: 7

Year of Publication: 2017

Affiliated Institutions:  Cardiocentro "Ernesto Che Guevara", Santa Clara, Cuba. Unidad de Hipertension y Riesgo Vascular, Hospital Clínic (IDIBAPS), Universidad de Barcelona, España. Department of Internal Medicine, Holbaek Hospital, and Centre for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, University of Southern Denmark, Denmark. Hipertension Arterial y Unidad Metabólica, Hospital Universitario, Fundación Favaloro, Argentina. Hypertension League - Federal University of Goias-Brasil. Director, Cardiometabolic Research Institute, Houston, Texas, USA. Hospital Universitario de San Juan, Alicante-Valencia, España. Fundació Hospital de l'EsperitSant, Barcelona, España. Instituto Mexicano de Salud Cardiovascular, Mexico. Universidad de Buenos Aires, Buenos Aires, Argentina. Universidad de la Frontera, Chile. Ministerio de Salud/Muncipal Health Office Campos do Jordão, Brasil. Clínica Kennedy, Guayaquil, Ecuador. Ministerio de Salud, Paraguay. Clínica Olivos, Buenos Aires, Argentina. Hospital de Alta Complejidad, Santa Cruz, Argentina. Ministerio de Salud Pública, Cuba. Universidad Médica de Holguín, Cuba. Instituto de Cardiologia y Cirugia Cardiovascular, Habana, Cuba. Universidad de Guadalajara, México. Instituto de Cardiología, Sanatorio Británico, Rosario, Argentina. CARDIOGOLF Lima, Perú. Hospital Italiano de Buenos Aires, Argentina. The University of Mississippi Medical Center, USA. Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School-the University of Queensland School of Medicine, USA. Sanatorio Allende y Universidad Nacional de Cordoba, Argentina. Public Health Foundation of India and Centre for Chronic Disease Control, Haryana, India. Department of Medical Sciences, Uppsala University, and Uppsala Clinical Research Center, Uppsala, Sweden. The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Department of Medicine. The University of Melbourne, Austin Health. Victoria, Australia. South African Medical Research Council Unit on Hypertension and Cardiovascular Disease, Hypertension in Africa Research Team,North-West University, South Africa. Research Institute, Fundación Oftalmológica de Santander and Medical School, Universidad de Santander, Colombia Colombia and Universidad Tecnologica Equinoccial, Facultad de Medicina Eugenio Espejo, Ecuador. H.Moinhos de Vento Porto Alegre, Brasil. Universidad de Valencia, España. Division of Cardiovascular Medicine, State University of New York, Downstate College of Medicine, New York. Hipertension Arterial y Unidad Metabólica, Hospital Universitario, Fundación Favaloro, Argentina; Instituto de Medicina Traslacional, Trasplante y Bioingenieria. Universidad Favaloro-CONICET, Argentina. Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization.Washington, USA. Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Canada. Istituto Auxologico Italiano, Centro Interuniversitario di Fisiologia Clinica e Ipertensione, University of Milan, Italia.

Abstract summary 

Hypertension is a leading risk factor for disease burden globally. An unresolved question is whether grade 1 hypertension (140-159/90-99mmHg) with low (cardiovascular mortality <1% at 10 years) to moderate (cardiovascular mortality ≥1% and <5% at 10 years) absolute total cardiovascular risk (CVR) should be treated with antihypertensive agents. A virtual international consultation process was undertaken to summarize the opinions of select experts. After holistic analysis of all epidemiological, clinical, psychosocial, and public health elements, this consultation process reached the following consensus in hypertensive adults aged <80 years: (1) The question of whether drug treatment in grade 1 should be preceded by a period of some weeks or months during which only lifestyle measures are recommended cannot be evidence based, but the consensus opinion is to have a period of lifestyle alone reserved only to patients with grade 1 "isolated" hypertension (grade 1 uncomplicated hypertension with low absolute total CVR, and without other major CVR factors and risk modifiers). (2) The initiation of antihypertensive drug therapy in grade 1 hypertension with moderate absolute total CVR should not be delayed. (3) Men ≥55 years and women ≥60 years with uncomplicated grade 1 hypertension should automatically be classified within the moderate absolute total CVR category, even in the absence of other major CVR factors and risk modifiers. (4) Statins should be considered along with blood-pressure lowering therapy, irrespective of cholesterol levels, in patients with grade 1 hypertensive with moderate CVR.

Authors & Co-authors:  Morales Salinas Alberto A Coca Antonio A Olsen Michael H MH Sanchez Ramiro A RA Sebba-Barroso Weimar K WK Kones Richard R Bertomeu-Martinez Vicente V Sobrino Javier J Alcocer Luis L Pineiro Daniel J DJ Lanas Fernando F Machado Carlos A CA Aguirre-Palacios Fernando F Ortellado Jose J Perez Gonzalo G Sabio Rodrigo R Landrove Orlando O Rodriguez-Leyva Delfin D Duenas-Herrera Alfredo A Rodriguez Portelles Ayelen A Parra-Carrillo Jose Z JZ Piskorz Daniel L DL Bryce-Moncloa Alfonso A Waisman Gabriel G Yano Yuichiro Y Ventura Hector H Orias Marcelo M Prabhakaran Dorairaj D Sundström J J Wang Jiguang J Burrell Louise M LM Schutte Alta E AE Lopez-Jaramillo Patricio P Barbosa Eduardo E Redon Josep J Weber Michael A MA Lavie Carl J CJ Ramirez Agustin A Ordunez Pedro P Yusuf Salim S Zanchetti Alberto A

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  41
Identifiers
Doi : 10.1016/j.cpcardiol.2017.03.001
SSN : 1535-6280
Study Population
Men,Women
Mesh Terms
Adult
Other Terms
Study Design
Cross Sectional Study
Study Approach
Country of Study
Publication Country
Netherlands